Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Carcinoma, Renal Cell × tivozanib × Clear all

Phase

Status

Completed 3 Withdrawn 2 Recruiting 2 Terminated 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 1 Solid Tumors 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Liver Neoplasms 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1

Interventions

Sunitinib 21 Nivolumab 21 pembrolizumab 18 Sorafenib 16 Everolimus 12 Cyclophosphamide 11 Interleukin-2 10 Bevacizumab 9 Radiosurgery 8 spartalizumab 7 pazopanib 7 Axitinib 7 fludarabine 6 aldesleukin 6 cabozantinib 5 Radiotherapy 5 Magnetic Resonance Spectroscopy 5 Ipilimumab 5 Immunohistochemistry 5 peginterferon alfa-2b 4 avelumab 4 atezolizumab 4 Introns 4 Gene Expression Profiling 4 Gemcitabine 4 fludarabine phosphate 3 Polymerase Chain Reaction 3 Nephrectomy 3 Irinotecan 3 Interferons 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01673386 2020-10-27

TAURUS

AVEO Pharmaceuticals, Inc.

Phase 2 Terminated

58 enrolled 7 charts

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡